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The experiment was carried out on 120 female white Wistar rats, to study the endothelio- and osteoprotective action of the
combination of rosuvastatin with L-norvaline in the model of experimental osteoporosis. It was found that, after ovariectomy
in rats, endothelial dysfunction of the vessels of the microcirculatory bed of bone tissue develops, leading to the appearance of
osteoporosis, but the combination of the studied drugs prevents the decrease in the level of microcirculation in the bone tissue,
thereby preventing the thinning of bone trabeculae and preventing the occurrence of microfractures in them.
1. Introduction
Themain cause of development of osteoporosis is the imbal-
ance of the key processes: process of bone resorption and
remodeling [1]. It is known that the blood supply plays a
significant role in the regeneration of bone tissue. Deteri-
oration of blood supply leads to a decrease in the number
of osteoblasts and inhibits their activity, while osteoclasts
activate their activity. Dysfunction of the endothelium of
microcirculatory vessels, most often, is the basis in the patho-
genesis of reducing microcirculatory blood flow in the bones
[2], which, in turn, leads to a disturbance of osteogenesis,
thereby causing osteoporotic changes in bone tissue [3].
In a number of experimental studies, the positive effects
of drugs possessing endotheliotropic properties on repair
and regeneration of bone tissue have been proved. These
include enalapril, losartan, and resveratrol [4–6]. It can be
assumed that, in addition to these drugs, a combination of
drugs consisting of rosuvastatin and L-norvaline possesses
the same endothelioprotective properties. Under the influ-
ence of this combined treatment, the flow of blood in the
microcirculation is normalized, leading to a slowdown in
the development of osteoporotic changes in the spongy bone
tissue. At present, there is no evidence in modern scientific
publications that this combination of drugs has been used
in the pharmacotherapy of osteoporosis; this confirms the
relevance of the research topic.
2. Objective
The objective of this paper is the analysis of the effectiveness
of pharmacological correction of experimental osteoporosis
with a combination of rosuvastatin with L-norvaline com-
pared with drugs strontium ranelate (Bivalos) and Calcium
D3 Nycomed.
3. Materials and Methods
All experimental manipulations were performed under gen-
eral anesthesia by intraperitoneal injection of a solution of
chloral hydrate at a dose of 300 mg/kg. Modeling of hypoe-
strogenic osteoporosis was done by performing bilateral
ovariectomy surgery to female Wistar rats of weight 200–250
g [2, 6]. After 56 days, in all the animals in the spongy
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bone tissue of the trochanteric region of the femur bone
were formed hypoestrogen-induced osteoporotic changes
(according to the results of histomorphometry).
The animals were divided into 5 groups. In the con-
trol group (n=20), the rats underwent an operation: false
ovariectomy (without removal of the ovaries). In group II
(n=20), the animals underwent surgery, bilateral ovariectomy
(osteoporosis model). As a placebo this group received for
eight weeks daily intragastrical paste of 1% starch.
In the rats of group III (n=20), after modeling of hypo-
estrogenic osteoporosis, after eight weeks, a combined treat-
ment with rosuvastatin 0.86 mg/kg and L-norvaline at a
dose of 10 mg/kg for four weeks was given. The animals in
groups IV andV (20 rats in each group) received, respectively,
Calcium D3 Nycomed at a dose of 85.7 mg/kg and strontium
ranelate (Bivalos) at a dose of 171 mg/kg from the ninth to the
twelfth week.The studied drugs were injected intragastrically
daily as a suspension in 1% starch paste.
After 12 weeks in the experimental animals, the index
of intraosseous microcirculation was measured in the
trochanteric region of the femur and the coefficient of endo-
thelial dysfunction (CED) was calculated on the basis of laser
Doppler flowmetry (LDF) data. Calculation and registration
of parameters of microcirculation and CED were performed
using a laser Doppler flowmetry Biopac system MP-100 and
a needle-shaped sensor TSD-144; the results obtained were
processed by the AcqKnowledge version 3.8.1-4.2.0 program.
The values of microcirculation were expressed in perfusion
units (PU) and CED in conventional units (standard units).
To assess the formation of osteoporotic disorders and the
effectiveness of therapy of the studied drugs, histomorphom-
etry of the proximal metaphysis of the femur was performed.
When calculating the width of the bone trabecula, ImageJ
version 1.39 was used. The values obtained were expressed in
micrometers (𝜇m).
4. Results
Whenmeasuring the parameters of intraosseous perfusion in
the trochanteric region of the femur in rats, the following was
found:
(i) In the control group (false ovariectomy): 99.91±3.41
PU
(ii) In group II (model of osteoporosis without treat-
ment): 58.75±3.76 PU
(iii) In group III (combination therapy with rosuvastatin
and L-norvaline): 88.02±3.03 PU
(iv) In group IV (therapy with Calcium D3 Nycomed):
56.89±2.02 PU
(v) In group V (therapy with strontium ranelate):
67.48±2.98 PU
Thus, it was found that the combination of rosuvastatin
and L-norvaline in the studied dosages increased the rates
of regional intraosseous microcirculation of the proximal
femur. Data of LDF-graphs in a group of rats that received
a combination of the studied drugs were statistically signif-
icantly different from those of animals with osteoporosis, as
well as rats treated with the drugs of comparison: Bivalos and
Calcium D3 Nycomed.
To clarify the role of endothelial dysfunction (ED) in the
formation of intraosseous microcirculation disorders, func-
tional vascular tests were performed: one-time intravenous
injection of solutions of acetylcholine and nitroprusside (at
doses of 40 𝜇g/kg and 30 𝜇g/kg, respectively). With the
introduction of these drugs, there was a decrease in the
microcirculatory blood flow, followed by normalization of the
microcirculation indices. The reason for this phenomenon is
that acetylcholine and nitroprusside cause systemic vasodi-
lation; that is, there is centralization of blood flow and,
consequently, a decrease in the velocity of blood flow volume
in bone tissue. The calculation of this coefficient was carried
out on the basis of the LDF-graph that is defined as the ratio
of the area of the triangle above themicrocirculation recovery
curve in response to the introduction of nitroprusside to the
area of the triangle above themicrocirculation recovery curve
in response to the introduction of acetylcholine.
In the control group the value of CED was 1.28±0.18; in
the group of rats with experimental osteoporosis CED was
2.57±0.23. These results indicate the formation of changes
leading to dysfunction of the endothelium of the blood
channel in the bone tissue after ovariectomy. When admin-
istering combined treatment with these drugs, a statistically
significant decrease in the coefficient of 1.68±0.25 was found.
Calcium D3 Nycomed and the strontium ranelate statisti-
cally significant changes in this indicator were not found
(2.64±0.17 and 2.44±0.19, respectively). The obtained data
indicate that the combination of the drugs under study,
in comparison with Calcium D3 Nycomed and strontium
ranelate, has endothelioprotective activity. This property
of this combination has a positive effect on intraosseous
microcirculation, which results in the stabilization of bone
remodeling processes, which prevents the progression of
the formation of osteoporotic disorders in the spongy bone
tissue.
This position is confirmed by the results of histolog-
ical studies. Microscopic morphological sections of the
trochanteric zones of the rat’s femur that received combined
treatment of rosuvastatin and L-norvaline are determined by
the normal microarchitecture of the bone tissue in compari-
son with the animals with osteoporosis (Figure 1).
An objective evaluation criterion for the formation of
osteoporotic shifts and the effectiveness of the treatment after
bilateral ovariectomy is histomorphometry. The mean width
of the bone trabeculae in the localization was calculated.
Thus, a significant decrease in the average width of bone tra-
beculae in animals with a model of osteoporosis (64.61±0.54
𝜇m)was found to be 33%higher than in the rats of the control
group (96.64±1.01 𝜇m).
In a morphometric study, it was found that the com-
bination of rosuvastatin with L-norvaline in the previously
indicated dosages prevented a decrease in the average width
of the bone trabeculae to a level of animals with experi-
mental osteoporosis by 30% (84.02±0.89 𝜇m). However, the
average width of the trabeculae did not reach the values of
the control rats but statistically significantly exceeded the
parameters obtained in animals treated with comparative
Journal of Osteoporosis 3
(a) (b) (c)
Figure 1:The histological picture of proximal metaphysis of the femoral bone (strained with hematoxylin and eosin, zoom, x100). (a) Control
group; (b) group with a model of osteoporosis, without treatment; (c) group treated with L-norvaline.
drugs: strontium ranelate (80.19±0.95 𝜇m) and Calcium D3
Nycomed (58.23±0.97 𝜇m).
Thus, the studied combination of drugs, three months
after the modeling of osteoporosis in rats, has a protective
effect, which is slowing down the thinning of the trabeculae
in the trochanteric region of the femur.
5. Discussion
The endothelial layer of the intraosseous vessels is an integral
part of the bone and plays a central regulatory role [7],
with significant metabolic activity, while performing various
functional activities, which include regulation of leukocyte
adhesion, regulation of vascular growth, atrombogenicity and
thrombogenicity of the vessel wall, and immune functions
[8]. Endothelial cells themselves produce a variety of biolog-
ically active substances that are involved in the regulation
of vascular tone [9]. A significant number of mediators
that are produced by the endothelial layer are vasocon-
strictors, angiotensin II and endothelin I, and vasodilators,
nitric oxide (NO), endothelial hyperpolarizing factor, and
prostacyclin [10]. Endothelial dysfunction is an imbalance
between vasodilating and vasoconstrictormediators, which is
characterized by a decrease in the production of vasodilators
with activation of the synthesis of vasoconstrictors. The
primary vasodilating mediator is nitric oxide, which as a
result of biosynthesis is extracted from the amino acid of L-
arginine with the participation of the endothelial nitric oxide
synthase (NO synthase) enzyme [11]. Decrease in expression
or transcription of NO synthase and a decrease of L-arginine
reserves availability, as well as the acceleration of nitric oxide
metabolism, lead to a disruption of its synthesis and, as a
result, endothelial dysfunction occurs. The metabolism of L-
arginine in the cells proceeds in two ways: the first one: under
the action of the digestion, it is hydrolyzed to ornithine and
urea; the second: transformation: L-arginine is hydrolyzed
to nitric oxide and citrulline, and it is catalyzed by NO
synthase. The enzymes arginase and NO synthase compete
with each other for a common substrate: L-arginine [10]. In
a number of studies, there was an increase in the activity of
arginase with the development of endothelial dysfunction.
Also, arginase inhibits the activity of nitric oxide synthase,
inhibiting the production of nitric oxide. The decrease in the
effect of arginase leads to an increase in the production of
nitric oxide, favorably affecting the normalization of vascular
function [11].
From the foregoing, it can be concluded that the use of
arginase inhibitors is necessary to increase the production of
nitric oxide, which helps prevent the formation of endothelial
dysfunction. Arginase inhibitors (such as L-norvaline) block
the enzyme arginase, while most likely preventing metamor-
phosis of L-arginine in urea and ornithine. Due to this, a sig-
nificant amount of L-arginine is cleaved under the influence
of NO synthase by the formation of NO.This positively affects
the regional microcirculation of the intraosseous structures,
maintaining within a reasonable range the homeostasis in the
bone tissue.
Another group of drugs, which is very popular in the
complex treatment of vascular pathology, are statins that
can improve endothelial function. Their pharmacological
actions are based on the fact that lipids normally cannot
penetrate through the intima of the vessels. When the barrier
function of the endothelium is violated, systemic and local
inflammatory mediators are produced under the influence
of risk factors (smoking, hypercholesterolemia, hyperinsu-
linemia, arterial hypertension, menopause, etc.), leading to
a decrease in the stability of endothelial NO synthase that
is leading to the development of endothelial dysfunction
[12]. In experimental models of hypercholesterolemia in
pigs, it was found that statins have a positive effect on the
function of endotheliocytes and improve the myocardial
perfusion. The improvement in endothelial function does
not depend on the concomitant decrease in cholesterol level
[13]. Preparations of this group can increase the activity of
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endothelial NO synthase in the culture of human endothelial
cells by stabilizing its mRNA. Subsequently, it was found that
statins stimulate the expression of endothelial NO synthase
mainly due to the effect on posttranscriptional mechanisms.
These substances also have other mechanisms of action
on the activity of endothelial NO synthase: they activate
protein kinase in endothelial cells, which in turn leads to
phosphorylation of endothelial NO synthase, which increases
its activity and stimulates NO synthesis. Also, there is the
ability of these drugs to increase the production of NO, while
inhibiting the expression of caveolin-1, which can reduce
the activity of endothelial NO synthase by binding to this
enzyme. This fact is confirmed by the results of experimental
studies in which it was clearly demonstrated that statins
improve cerebral blood flow and have a cardioprotective
effect with an indirect increase in the secretion of NO in the
endothelium, independent of their hypolipidemic action.
Statins have the ability to increase the activity of endothe-
lial NO synthase. Stimulation of NO production in the
endothelium is a characteristic of all statins and does not
depend on their effect on cholesterol synthesis [13, 14].
Moreover, the use of modern statins, including rosuvas-
tatin, positively affects the elastic properties of the vascular
wall and reduces endothelial dysfunction, increasing the
functional activity of endotheliocytes. Stimulation of NO
production in the endothelium is a characteristic of all statins
and does not depend on their effect on the synthesis of
cholesterol. These properties have a positive effect on the
state of intraosseous microcirculation, therefore indirectly
improving the trophism of bone tissue, including positively
affecting osteoregeneration.
In view of the foregoing, it can be assumed that L-
norvaline and rosuvastatin, despite having different phar-
macokinetic mechanisms of action, potentiate the actions
of each other when they are in combined therapy, which
positively affects the process of bone remodeling.
6. Conclusion
(1) The combination of rosuvastatin with L-norvaline in
the indicated dosages on the chosen model of pathol-
ogy has a significant endothelioprotective effect. It
is manifested by the decrease in the coefficient of
endothelial dysfunction, which predisposes to the
development of microcirculatory disorders
(2) The combination of rosuvastatin with L-norvaline
effectively prevents the decrease in blood flow in
the bone tissue of the trochanteric region of the
femur, keeping it at a level close to animals without
osteoporosis
(3) The combination of rosuvastatin with L-norvaline
has more pronounced osteoprotective effect than
strontium ranelate and Calcium D3 Nycomed
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